This is the only ITP-validated lifespan extension drug in non-rapamycin / non-17α-estradiol Class III evidence — male mice +22%, female mice +5% lifespan extension at standard dose, replicated across multiple sites (Harrison 2014, 2019). Mechanism likely via attenuated post-prandial glucose spikes + altered gut microbiome (SCFA production). For Dylan at 20 with healthy glucose tolerance, no current case — but acarbose is plausibly the most evidence-backed longevity-positioning drug after rapamycin + metformin, and the GI side effects make it tractable to test (start ~25 mg with first carby meal, titrate to tolerance). WATCH-LIST — would flip to OPTIONAL-ADD in middle age if metabolic markers slip OR if Dylan wanted to add one more longevity tool with the cleanest mouse lifespan signal of the bunch.